Trial Profile
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Abiraterone acetate; Antiandrogens; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms The CHAARTED2 Trial
- 09 Mar 2023 Planned End Date changed from 1 Apr 2025 to 1 Apr 2026.
- 09 Mar 2023 Planned primary completion date changed from 1 Sep 2023 to 30 Jun 2024.
- 09 Mar 2023 Status changed from recruiting to active, no longer recruiting.